Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The p53-mediated lysosome–mitochondria apoptosis signaling pathway describes a sequence of molecular events by which the tumor suppressor protein p53 initiates programmed cell death. Upon cellular stress (such as DNA damage), p53 activation causes destabilization of lysosomal membranes, releasing proteases that damage mitochondria. Subsequent mitochondrial outer membrane permeabilization leads to the release of apoptogenic factors such as cytochrome c, eventually activating caspases and leading to apoptosis. This pathway plays a major role in tumor suppression by eliminating damaged or potentially cancerous cells. In cancer, dysregulation of p53 or components of this pathway frequently leads to resistance to cell death and tumor progression.
Not applicable to the pathway as a whole, but drugs that induce p53 activity (by causing DNA damage) can trigger this pathway, leading to cell death via lysosomal destabilization and mitochondrial permeabilization.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on p53-mediated lysosome–mitochondria apoptosis signaling pathway (null).